by San Rocco Therapeutics | Sep 1, 2022 | News
TrialSite News: FDA Rejects Petition for Review of Gene Therapy Product for Safety Concerns Involving Vulnerable Patient Population Is the filing of a citizen petition with the U.S. Food and Drug Administration (FDA) an appropriate action for requesting review of a...
by San Rocco Therapeutics | Aug 29, 2022 | News
Informa: US FDA Quashes Citizen Petition Against Bluebird’s Zynteglo That Cited Patent, Safety Concerns San Rocco, whose potential rival gene therapy for thalassemia is in preclinical development, had wanted FDA to delay approval of bluebird’s BLA until resolution of...
by San Rocco Therapeutics | Aug 19, 2022 | News
Trialsite News: FDA Approves First Gene Therapy for Beta-Thalassemia Patients Who Require Regular Red Blood Cell Transfusions: $2.8m Cost Gene therapy-focused biotech venture bluebird bio announced recently that the U.S. Food and Drug Administration (FDA) approved...
by San Rocco Therapeutics | Jul 15, 2022 | News
EIN Presswire: Megan Euker, Acclaimed Project Manager, Wins Coveted Award SAN ROCCO THERAPEUTICS (SRT) Announces LOS ANGELES, CA, UNITED STATES, July 15, 2022 /EINPresswire.com/ — Megan Euker, acclaimed Project Manager, receives Fulbright U.S. Scholar Award to...
by San Rocco Therapeutics | Jul 13, 2022 | News
Trialsite News: “Family Man” Saga: Amended Complaint Filed by San Rocco Therapeutics Against Memorial Sloan Kettering, New Charge of Fraudulent Inducement Settlement Broken In a short summary of these long years, TrialSite continues to chronicle Patrick...
by San Rocco Therapeutics | Apr 12, 2022 | News
Business Wire: San Rocco Therapeutics, LLC (“SRT”) Pushes Clinical Trial for a Curative Treatment for Beta-Thalassemia and Sickle Cell Disease TAMPA, Fla.–(BUSINESS WIRE)–Using the SRT vector and myelosuppressive preparation therapy, Memorial Sloan...
